Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609442 | PMC |
| http://dx.doi.org/10.4103/sni.sni_218_17 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Doxycycline Versus Vancomycin for the Treatment of Methicillin-Resistant Acute Pulmonary Exacerbations in People With Cystic Fibrosis.
Ann Pharmacother
January 2025
College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Background: Among people with cystic fibrosis (PwCF), methicillin-resistant (MRSA)-associated acute pulmonary exacerbations (APEs) have been increasing in prevalence and can cause rapid declines in lung function and increased mortality. Fortunately, since 2019, incidence has started to decline.
Objective: The purpose of this study was to evaluate if doxycycline has comparable efficacy to vancomycin for the treatment of APEs in PwCF.
Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective Na1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain.
Pain Ther
January 2025
Research Management, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, 02210, USA.
Introduction: There is a high unmet need for safe and effective non-opioid medicines to treat moderate to severe pain without risk of addiction. Voltage-gated sodium channel 1.8 (Na1.
View Article and Find Full Text PDFPharmacotherapy from Pre-COVID to Post-COVID: Longitudinal Trends and Predictive Indicators for Long COVID Symptoms.
Biomedicines
November 2024
Department of Pulmonary Medicine, Amsterdam UMC, 1105 AZ Amsterdam, The Netherlands.
Background/objectives: A significant number of COVID-19 cases experience persistent symptoms after the acute infection phase, a condition known as long COVID or post-acute sequelae of COVID-19. Approved prevention and treatment options for long COVID are currently lacking. Given the heterogeneous nature of long COVID, a personalized medicine approach is essential for effective disease management.
View Article and Find Full Text PDFPrimum Non Nocere: The Onus to Characterize the Potential Harms of Psychedelic Treatment.
Am J Psychiatry
January 2025
Department of Psychiatry, Center for the Neuroscience of Psychedelics, Massachusetts General Hospital, Boston (Ghaznavi, King, Rosenbaum); Department of Cardiology, Massachusetts General Hospital, Boston (Ruskin); Department of Psychiatry and Neurology, Chemical Neurobiology Laboratory, Center for the Neuroscience of Psychedelics, Massachusetts General Hospital, Boston (Haggerty); Havard Medical School, Boston (Ghaznavi, Ruskin, Haggerty, King, Rosenbaum).
The last few years have seen exponential growth in interest, investment, advocacy, and research into psychedelics as therapeutics. This reflects an optimism about the potential promise of psychedelics as therapeutics. As with all therapeutic interventions, research is needed not only into their benefits but also potential risks.
View Article and Find Full Text PDFEffectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform.
EClinicalMedicine
January 2025
P95 Epidemiology and Pharmacovigilance, Koning Leopold III Laan 1, Leuven 3001, Belgium.
Background: Prior studies have reported lower effectiveness of XBB.1.5-adapted vaccines against hospitalization related to the Omicron JN.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!